Overview
Ipamorelin is a pentapeptide ghrelin-receptor agonist developed in the late 1990s by Novo Nordisk as a selective growth-hormone secretagogue. The molecule was designed to stimulate pulsatile growth-hormone release without the parallel rises in cortisol, prolactin or aldosterone that complicate earlier GHRPs.
In preclinical and early human studies the compound produced dose-dependent, transient elevations in plasma growth hormone (GH) without measurably affecting HPA-axis or lactotroph activity. This selectivity is the central reason it remains a reference compound in GH-secretagogue research.
Clinical development was halted at phase II for postoperative ileus, not because of safety signals, but because the primary endpoint was not met. The molecule is therefore a well-characterised research tool with a substantial published safety record but no approved therapeutic indication.
Mechanism of Action
Ipamorelin binds the growth-hormone secretagogue receptor type 1a (GHS-R1a) on somatotrophs in the anterior pituitary. Receptor activation triggers a G_q/PLC signalling cascade culminating in intracellular calcium release and exocytosis of GH-containing vesicles.
The pulsatile GH release that follows mirrors the natural diurnal pattern more closely than continuous GHRH infusion, which is hypothesised to preserve receptor sensitivity over longer dosing windows.
Selectivity for GHS-R1a over closely related receptors — particularly the absence of corticotroph activation — distinguishes ipamorelin from earlier GHRPs (GHRP-2, GHRP-6) which produced clinically meaningful cortisol and prolactin elevations.
Research Summary
- Selective GH release without measurable HPA-axis activation, established in the compound's original pharmacological characterisation. [1]
- Human pharmacokinetic-pharmacodynamic modelling confirmed a short plasma half-life and dose-dependent GH response. [2]
- GHRH and ghrelin-receptor agonists act synergistically on GH secretion, a pattern documented across the GH-secretagogue class in healthy men. [3]
- Secretagogue responsiveness and recovery from GH-induced feedback vary by sex and hormonal status across repeated-dosing human studies. [4]
What we don't know yet
- Long-term effects on IGF-1, glucose handling and insulin sensitivity in humans are not well characterised.
- Optimal dosing intervals for sustained GH benefit without tachyphylaxis remain debated in the literature.
- Cardiovascular safety in older populations has not been studied at length.
Protocol Considerations
Research framing only. The Protides Research Library does not provide dosing guidance for human use. The figures below summarise published research-protocol ranges and storage conditions; they are not clinical recommendations.
Stack Interactions
Storage & Handling
- Lyophilised
- −20 °C, desiccated. Stable for at least 24 months.
- Reconstituted
- 2–8 °C in bacteriostatic water. Use within 21 days.
- Shelf life
- Lyophilised ≥ 24 months at −20 °C. Reconstituted ~21 d at 2–8 °C.
FAQ
How does ipamorelin differ from GHRP-2 / GHRP-6?
It binds the same receptor (GHS-R1a) but with greater selectivity — no measurable cortisol or prolactin elevation at studied doses.
Does ipamorelin work like GHRH?
No. GHRH binds the GHRH receptor; ipamorelin binds the ghrelin receptor. The downstream effect (GH release) overlaps, but the pathways are distinct.
Is it approved for clinical use?
No. Clinical development was halted; it remains a research compound.
Why is it often stacked with CJC-1295?
The two compounds activate complementary pituitary pathways; combined administration produces a larger GH pulse than either alone in animal data.
What is the typical research half-life?
Approximately two hours in plasma in human studies.
Does it raise cortisol?
Published phase I data did not detect a meaningful cortisol response at studied doses.
References
- [1]Ipamorelin, the first selective growth hormone secretagogueEur. J. Endocrinol., 1998
- [2]
- [3]Gonadal status and body mass index jointly determine GH-releasing hormone/GH-releasing peptide synergy in healthy menJ. Clin. Endocrinol. Metab., 2008
- [4]Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and menJ. Clin. Endocrinol. Metab., 2011
